ProfileGDS5678 / 1416531_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 85% 84% 86% 85% 83% 85% 84% 85% 85% 85% 85% 85% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5721987
GSM967853U87-EV human glioblastoma xenograft - Control 26.34885
GSM967854U87-EV human glioblastoma xenograft - Control 36.2355584
GSM967855U87-EV human glioblastoma xenograft - Control 46.6506686
GSM967856U87-EV human glioblastoma xenograft - Control 56.473685
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8918183
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1723985
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1744184
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3138685
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3437485
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4060185
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4985485
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4220685
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1514184